Recruitment

Recruitment Status
Active, not recruiting
Estimated Enrollment
400

Summary

Conditions
  • Lung Cancer
  • Non -Small Cell Lung Cancer
Type
Observational
Design
Observational Model: CohortTime Perspective: Prospective

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

The aim of the study is to assess the real-world patient experience by evaluating the patients' quality of life, treatment toxicities, and clinical measures over a 6-month period. The ultimate goal of this research is to improve patient-physician treatment decisions, so that the patient's personal t...

The aim of the study is to assess the real-world patient experience by evaluating the patients' quality of life, treatment toxicities, and clinical measures over a 6-month period. The ultimate goal of this research is to improve patient-physician treatment decisions, so that the patient's personal treatment goals and quality of life have the highest chances of being fulfilled. Aim 1. To track the toxicities/side-effects of FDA approved molecular targeted agents, immunotherapies, and combinations of treatments for NSCLC in a clinical setting for six months. Aim 2. To assess the impact of these treatment regimens on patient toxicities, symptoms, function, and quality of life, after adjustment for clinical factors and patient characteristics during the 6 month follow-up period.

Tracking Information

NCT #
NCT02803333
Collaborators
  • PatientsLikeMe
  • Ohio State University Comprehensive Cancer Center
  • AstraZeneca
  • Genentech, Inc.
Investigators
Principal Investigator: Matthew Schabath, Ph.D. H. Lee Moffitt Cancer Center and Research Institute